Current & Emerging Payment Models
CMS and the Office of the Assistant Secretary for Planning and Evaluation issued their report to Congress.
The Centers for Medicare & Medicaid Services today announced that it will delay indefinitely the payment penalty period of the Appropriate Use Criteria program for advanced imaging services. The program, which was set to potentially go into effect on Jan. 1, 2023, requires imaging provider…
CMS issued its calendar year 2023 proposed rule for the home health prospective payment system, which would reduce net HH payments by $810 million in calendar year 2023 relative to CY 2022.
June 17, 2022
The Honorable Chiquita Brooks-LaSure Administrator
Centers for Medicare & Medicaid Services
Hubert H. Humphrey Building
200 Independence Avenue, S.W.
Room 445-G
Washington, DC 20201
AHA's submitted the following comments on the fiscal year (FY) 2023 LTCH prospective payment system (PPS) proposed rule to CMS.
The AHA supports the Centers for Medicare & Medicaid Services’ proposal to delay the January 2023 start of the Radiation Oncology Model.
Responding to a recent request for input from the field, the AHA urged the Center for Medicare and Medicaid Innovation to balance the risk and reward in its alternative payment models “in a way that reflects the significant investments required to launch and maintain APM participation.”
Responding to a recent request for input from the field, the AHA yesterday urged the Center for Medicare and Medicaid Innovation to balance the risk and reward in its alternative payment models “in a way that reflects the significant investments required to launch and maintain APM participation.”
AHA commented on recent Medicare Payment Advisory Commission discussions on possible approaches to reducing spending on Part B drugs and biologicals, improving alternative payment models, and revising the hospital wage index.
The Centers for Medicare & Medicaid Services released Medicare Part B billing codes and payment allowances for reporting and administering single booster doses of the Moderna and Johnson & Johnson COVID-19 vaccines to eligible adults as authorized Oct. 22 by the Food and Drug Administration.